Physician profile
Robert Francis Straub
NPI 1083636856
$3,822.45
in general payments reported to CMS, 2019-2025
28 companies · $676 in 2025
The $676 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $407 · 2020: $52.16 · 2021: $501 · 2022: $1,080 · 2023: $514 · 2024: $591 · 2025: $676.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,782.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,781.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,336.91 | 2019-2025 | Skyrizi, Rinvoq |
| Pfizer INC. | $409.86 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $348.04 | 2019-2021 | |
| Medtronic, INC. | $345.29 | 2021-2025 | Eea |
| Janssen Biotech, INC. | $276.82 | 2019-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $130.48 | 2019-2024 | Gattex, Entyvio |
| Genzyme Corporation | $127.53 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $122.74 | 2022 | |
| Merck Sharp & Dohme LLC | $93.20 | 2023-2024 | Dificid |
| Qol Medical, LLC | $88.48 | 2022-2024 | Sucraid |
| Nestle Healthcare Nutrition INC. | $65.18 | 2021-2022 | |
| Celgene Corporation | $47.49 | 2021-2023 | Zeposia |
| Redhill Biopharma INC. | $46.58 | 2021-2022 | |
| Daiichi Sankyo INC. | $46.16 | 2019-2024 | Injectafer |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.89 | 2019-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.81 | 2023-2024 | Cyltezo |
| Braintree Laboratories, INC. | $35.97 | 2021-2024 | Suflave, Sutab |
| Gilead Sciences, INC. | $28.66 | 2019-2025 | |
| Allergan, INC. | $25.85 | 2019 | |
| Ardelyx, INC. | $24.53 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $22.33 | 2024 | Dupixent |
| Organon LLC | $21.94 | 2022 | |
| Celltrion USA INC. | $20.56 | 2025 | Vegzelma |
| Boston Scientific Corporation | $17.77 | 2024 | Koala |
| Ironwood Pharmaceuticals, INC | $16.18 | 2022 | |
| Fresenius Kabi USA, LLC | $15.99 | 2023 | Idacio |
| Evoke Pharma, INC. | $15.40 | 2023 | Gimoti |
| Ferring Pharmaceuticals INC. | $12.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Straub listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.